[EN] SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) O-LINKED LIGANDS AND METHODS OF USE THEREOF<br/>[FR] LIGANDS O-LIÉS AU RÉCEPTEUR SÉLECTIF ANDROGÉNIQUE (SARD) ET PROCÉDÉS D'UTILISATION ASSOCIÉS
申请人:[en]UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
公开号:WO2024010817A2
公开(公告)日:2024-01-11
This disclosure is directed to selective androgen receptor degrader (SARD) compounds, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, spinal (and) bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.